1. Brown GC, Sharma S, Brown MM, Garrett S. Evidence-based medicine and cost-effectiveness. J Healthcare Fin 1999;26:14-23.

2. Brown GC, Brown MM, Sharma S, Tasman W, Brown H. Cost-effectiveness of therapy for threshold retinopathy of prematurity. Pediatrics 1999;104(4):e47.

3. Brown GC, Sharma S, Brown MM, Garrett S. Evidence-based medicine and cost-effectiveness. J Healthcare Fin 1999;26:14-23.

4. Brown GC, Brown MM, Sharma S, Tasman W, Brown H. Cost-effectiveness of therapy for threshold retinopathy of prematurity. Pediatrics 1999;104(4):e47.

5. Shah G, Sharma S, Brown GC. Choroidal neovascularization following argon laser photocoagulation for macular edema associated with branch retinal vein obstruction. Can J Ophthalmol 2000;35:437-430.

6. Brown GC, Brown MM. Is prophylactic PRP in ischemic CRVO a good idea? Rev Ophthalmology 2000, 7:106,108,111.

7. Brown MM, Brown GC, Sharma S. Cost-effective analysis. The value component of evidence-based medicine. Cost-utility of treatment for acute, non-arteritic central retinal artery obstruction. Evidence-Based Eye 2000;1:243-247.

8. Brown MM, Brown GC, Sharma S. Cost-effective analysis. The value component of evidence-based medicine. Cost-utility analysis of cataract surgery utilizing decision analysis Evidence-Based Eye Care. 2000;1:297-301.

9. Brown MM, Brown GC, Sharma S. Cost-effective analysis can help improve the U.S. health care system. Ocular Surgery News 2000;18:16-17.

10. Brown MM, Brown GC, Sharma S. Cost-effective analysis. The value component of evidence-based medicine. Cost-utility analysis of cataract surgery utilizing decision analysis Evidence-Based Eye Care. 2000;1:297-301.

11. Brown MM, Brown GC, Sharma S. Cost-effective analysis. The value component of evidence-based medicine. Cost-effective analysis: Cataract surgery and sensitivity analysis. Evidence-Based Eye Care 2001;2:55-59.

12. Brown MM, Brown GC, Sharma S. Cost-effective analysis. The value component of evidence-based medicine. Cost-effective analysis: Diabetic vitrectomy. Evidence-Based Eye Care 2001;2:117-121.

13. Sharma S, Hollands H, Brown GC, Brown MM, Shah G, Sharma SM. The cost-effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy Curr Opin Ophthalmol 2001;12:230-234.

14. Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001;108:2051-2059.

15. Brown MM, Brown GC, Sharma S. Cost-effective analysis. The value component of evidence-based medicine. The four types of economic analysis. Evidence-Based Eye Care 2001;2:179-183.

16. Brown GC, Brown MM, Sharma S. Cost-effective analysis can help improve the U.S. health care system. Ocular Surgery News, Asia-Pacific Edition, 2001;12:40-41.

17. Brown MM, Brown GC, Sharma S. Cost-effective analysis. The value component of evidence-based medicine. Cost-utility of treatment for acute, non-arteritic central retinal artery obstruction. Evidence-Based Eye 2000;1:243-247.

18. Brown MM, Brown GC, Sharma S. Cost-effectiveness analysis. Types of healthcare economic analyses. Evidence-Based Eye Care 2002;4:212-217.

19. Brown GC, Brown MM, Sharma S, et al. Incremental cost-effectiveness of laser therapy for visual loss secondary to branch retinal vein occlusion. Ophthalmic Epidemiology 2002;9:1-10.

20. Membreno J, Brown MM, Brown GC, Sharma S, Beauchamp G. A cost-utility analysis of therapy for amblyopia. Ophthalmology 2002;109:2265-2271.

21. Fineman MS, Vander J, Regillo CD, Fineman SW, Brown GC. Hypopyon uveitis in immunocompetent patients treated for Mycobacterium avium complex pulmonary infection with rifabutin. Retina 2001;21:531-533.

22. Benson WE, Regillo CD, Vander JF, Tasman W, Smith AF, Brown GC, Ho AC, McNamara JA. Patient-initiated second medical opinions: Their necessity and economic cost. Retina 2001;21:633-638.

23. Brown GC, Brown MM, Sharma S. Cost-effective analysis can help improve the U.S. health care system. Ocular Surgery News, Asia-Pacific Edition, 2001;12:40-41.

24. Busbee B, Brown MM, Brown GC, Sharma S. Incremental cost-effectiveness of initial cataract surgery. Ophthalmology 2002;109:606-612.

25. Brown GC, Brown MM, Sharma S, Busbee B. A cost-utility analysis of interventions for proliferative vitreoretinopathy. Am J Ophthalmol 2002;133:365-372.

26. Brown MM, Brown GC. Cost-utility analysis, The foundation of value-based medicine. A cost-utility analysis of senile entropion repair. Evidence-Based Eye Care 2003;4:114-118.

27. Brown MM, Brown GC. Cost-Utility Analysis. The Foundation of Value-Based Medicine. The calculation of value conferred by cataract surgery. Evidence-Based Eye Care 2003;4:164-169.

28. Busbee B, Brown MM, Brown GC, Sharma S. A cost-utility analysis of cataract surgery in the second eye. Ophthalmology 2003;110:2310-2317.

29. Brown MM, Brown GC Luo B. Value-Based Medicine. The calculation of the costs associated with cataract surgery. The value component of evidence-based medicine. Evidence-Based Eye Care 2003;216-222.

30. Brown MM, Brown GC. Cost-Utility Analysis. The Foundation of Value-Based Medicine. The calculation of value conferred by cataract surgery. Evidence-Based Eye Care 2003; 4:164-169.

31. Busbee B, Brown MM, Brown GC, Sharma S. A cost-utility analysis of laser photocoagulation for extrafoveal choroidal neovascularization. Retina 2003;23: 279-287.

32. Brown MM, Brown GC, Sharma S. Value-based medicine and vitreoretinal diseases. Curr Opin Ophthalmol 2004;15:167-172.

33. Brown GC, Brown MM. Cost-utility analysis. The foundation of value-based medicine. Cataract surgery in the second eye. Evidence-Based Eye Care 2004; 5:112-120.

34. Brown GC, Brown MM. Cost-utility analysis. The foundation of value-based medicine. The dramatic effect of discounting. Evidence-Based Eye Care 2004;5:180-184.

35. Brown MM, Brown GC. Cost-utility analysis, the foundation of value-based medicine. Value and cost-utility: Two critical outcomes. Evidence-Based Eye Care 2004;5:234-238.

36. Brown GC, Brown MM. Cost-utility analysis, the foundation of value-based medicine. Pharmacoeconomics. 56,000 Ways to Treat Glaucoma. Evidence-Based Eye Care 2004;5:192-193.

37. Brown GC, Brown MM, Campanella J, Beauchamp GR. The cost-utility of photodynamic therapy in eyes with neovascular age-related macular degeneration. A reappraisal with 5-year data. Am J Ophthalmol 2005;140:679-687.

38. Brown MM, Brown GC. How to interpret a healthcare economic analysis. Curr Opin Ophthalmol 2005;16:191-194.

39. Brown GC. 56,000 Ways. No Way. Curr Opin Ophthalmol 2006;17:219-222.

40. Brown MM, Brown GC, Kertes P. Value-based medicine analysis. Ophthalmic cost-utility analyses. Evidence-Based Ophthalmology 2007;8:181-187.

41. Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration Ophthalmology 2007;114:1170-1178.

42. Brown GC, Brown MM, Brown HC. Cost-utility analysis. The foundation of value-based medicine: Is a new antibiotic cost-effective? Evidence-Based Ophthalmology 2007;8:119-125.

43. Brown MM, Brown GC, Brown H. Value-based medicine and interventions for macular degeneration. Curr Opin Ophthalmol 2007;18:194-200.

44. Brown GC, Brown MM, Brown H, Godshalk AN. Pharmacoeconomics and macular degeneration. Curr Opin Ophthalmol 2007;18:206-211.

45. Brown MM, Brown GC, Kertes P. Cost-utility analysis. Value-based medicine analysis: ophthalmic cost-utility analyses. Evidence-Based Ophthalmology 2007;8:181-7.

46. Brown MM, Brown GC. First and second eye models revisited. Evidence-Based Ophthalmology 2007;8:249-253.

47. Beauchamp CL, Beauchamp GR, Felius J, Stager DR, Brown G, Brown M, Felius J. The cost-utility of strabismus surgery in adults J Am Soc Ped Ophthalmol 2007:10:394-9.

48. Brown GC, Brown MM. Factoring Treatment Cost into Retina Therapy What should be the priorities for vitreoretinal interventions? And at what cost? Review of Ophthalmology Sept 7, 2007. On the Internet @ http://www.revophth.com/ publish/content/1_13515.htm.

49. Brown MM, Brown GC, Kertes P. Value-based medicine analysis. Ophthalmic cost-utility analyses. Evidence-Based Ophthalmology 2007;8:181-187.

50. Brown GC, Brown MM. Factoring treatment cost into retina therapy. What should be the priorities for vitreoretinal interventions? And at what cost? Rev Ophthalmol, Vol 14, 9-7-2007.

51. Brown GC, Brown MM. Factoring treatment cost into retina therapy. What should be the priorities for vitreoretinal interventions? And at what cost? Rev Ophthalmol, Vol 14, 9-7-2007.

52. Brown MM, Brown GC, Brown HC, Irwin B, Brown KS. The comparative effectiveness and cost-effectiveness of vitreoretinal interventions. Curr Opin Ophthalmol 2008;19:202-207.

53. Brown MM, Brown GC, Kertes, P. Value-based medicine analysis. Cost-utility standards. Evidence-Based Ophthalmology 2008;9:136-141.

54. Brown MM, Brown GC, Kertes, P. Value-Based Medicine Analysis. Value-Based Medicine cost-utility analysis. Recent value measures and cost-utilities. Evidence-Based Ophthalmology 2008;9:203-9.

55. Brown GC, Brown MM, Kertes P. Value-Based Medicine Analysis. Direct versus societal costs. Evidence-Based Ophthalmology 2008;9:63-69.

56. Brown GC, Brown MM, Brown H, Peet JS. A value-based medicine analysis of ranibizumab (MARINA Study) for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 2008;115:1039-1045.

57. Gupta O, Brown GC, Brown MM. A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery. Am J Ophthalmol. 2008;145:923-8. Epub 2008 Mar 10.

58. Roe RH, Lass JH, Brown GC, Brown MM. The cost-effectiveness of penetrating keratoplasty for keratoconus. Cornea 2008; 27:1001-7.

59. Brown MM, Brown GC ,Brown HC, Irwin B, Brown KS. The comparative effectiveness and cost-effectiveness of vitreoretinal interventions. Curr Opin Ophthalmol 2008;19:202-207.

60. Brown MM, Brown GC. Cost-effectiveness. Reply to the editor. Ophthalmology 2008;115:1433.

61. Brown GC, Brown MM, Kertes P. Value-based medicine, cost-utility analysis. The value of commonly used pharmaceuticals. Evidence-Based Ophthalmology 2009;10:61-66.

62. Brown MM, Luo B, Brown HC, Brown GC. Comparative effectiveness Its role in the healthcare system Curr Opin Ophthalmol 2009;20:188-194.

63. Brown GC, Brown MM, Kertes P. Comparative effectiveness and cost-effectiveness analyses. Value-Based Medicine® standards. Evidence-Based Ophthalmology 2009;10:232-8.

64. Brown MM, Brown GC, Brown HC, Irwin B, Roth Z. Comparative effectiveness and cost-effectiveness analyses of VEGF-A inhibitor and 90Sr brachytherapy for neovascular macular degeneration. Evidence-Based Ophthalmology 2009; 10:107-122.

65. Brown GC, Brown MM. Comparative effectiveness. Curr Opin Ophthalmol. 2009 May;20(3):147-50.

66. Brown GC, Brown MM, Brown HC, Peet J, Roth Z. Value-Based Medicine Analysis. Topical cyclosporine (Restasis) cost-utility analysis. Evidence-Based Ophthalmology 2009;10:166-71.

67. Brown MM, Brown GC. Cost-utility analysis. The pearl in the crown. Can J Ophthalmol 2010; 45:211-4.

68. Brown GC, Brown MM, Kertes P. Comparative effectiveness and cost-effectiveness analyses. Federal interventions necessary. Evidence-Based Ophthalmology 2010;12:58-65.

69. Brown GC, Brown MM, Leiske HB, Leiske AP, Brown KS. Value-Based Medicine, cost-utility analysis. Healthcare costs: Are they crippling our economy? Evidence-Based Ophthalmol 2010;11:121-7.

70. Brown GC, Brown MM, Leiske HB, Leiske AP, Brown KS. Value-Based Medicine, cost-utility analysis. What is cost-effective? Evidence-Based Ophthalmol 2010;11:180-6.

71. Brown GC, Brown MM, Kertes P. Comparative effectiveness and cost-effectiveness analyses: 27,000,000 possible input variants. Evidence-Based Ophthalmology 2011;12:52-7.

72. Brown GC, Brown MM, Lieske HB, Lieske PA, Brown KS. Comparative effectiveness and cost-effectiveness analyses on the Implantable Miniature Telescope. Ophthalmology. 2011 Sep;118(9):1834-43. Epub 2011 Jul 2.

73. Brown GC, Brown MM, Kertes P, Lieske HB, Lieske PA. Brown KS. Value-Based Medicine® Comparative Effectiveness and Cost-Effectiveness Analyses. 17.3% and Counting. Evidence-Based Ophthalmol 2011;12:108-14.

74. Brown GC, Brown MM, Leiske HB, Leiske AP, Brown KS. Value-Based Medicine® comparative effectiveness and cost-effectiveness analyses. Oral vitamin, and zinc supplements for the treatment of atrophic age-related macular degeneration. Evidence-Based Ophthalmol 2011;12:160-7.

75. Brown GC, Brown MM, Kertes P, Stein J. Value-Based Medicine Analysis. Cost-Utility Analysis. The foundation of Value-Based Medicine. Guidelines to master when performing or evaluating a cost-utility analysis. Evidence-Based Ophthalmol 2011;12:218-23.

76. Brown MM, Brown GC, Lieske HB, Lieske PA. Preference-based comparative effectiveness and cost-effectiveness: a review and relevance of Value-Based Medicine for vitreoretinal interventions. Curr Opin Ophthalmol. 2012 May;23(3):163-74, 2012 Apr 5. [Epub ahead of print]

77. Brown GC, Brown MM, Menezes A, Busbee BG, Lieske HB, Lieske PA. Cataract surgery cost-utility revisited in 2012. A new economic paradigm. Ophthalmology 2013; 120:2367-76.

78. Brown MM. Brown GC. Update on Value-Based Medicine©. Curr Opin Ophthalmol 2013 May;24(3):183-9. doi: 10.1097/ICU.0b013e32835ff189.

79. Brown GC. We are producers of patient value and financial value. Curr Opin Ophthalmol 2013;24:181-2.

80. Brown GC, Brown MM, Menezes A, Busbee B, Lieske HB, Lieske PA. Reply to the Editor. Re: Brown et al.: Cataract surgery cost utility revisited in 2012: a new economic paradigm. (Ophthalmology 2013;120:2367-76) Ophthalmology 2015’122:e18).

81. Brown GC, Brown MM, Turpcu A, Rajput Y. The cost-effectiveness of ranibizumab therapy for the treatment of diabetic retinopathy. Ophthalmology. 2015; 122:1416-25. doi: 10.1016/j.ophtha.2015.03.032. Epub 2015 Apr 29.

82. Brown G C, Stein JD, Brown MM, Spaeth GL, Wilson RS. Cost-utility analysis of timolol for the treatment for open-angle glaucoma. J Ophthalmol. 2015, 1(2): 008.

83. Brown GC, Brown MM, Lieske HB, Lieske PA, Brown KS. A Value-Based Medicine analysis of genetic testing for neovascular macular degeneration. Int J Ret Vitreous 2015:1:19. DOI: 10.1186/s40942-015-0016-5.

84. Olk RJ, Peralta E, Gierhart DL, Brown GC Brown MM. Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration. An interventional comparative study and cost-effectiveness analysis. Int J Ret Vitreous 2015:1:22 DOI: 10.1186/s40942-015-0019-2.

85. Brown GC, Brown MM. Value-Based Medicine and pharmacoeconomics. Dev Ophthalmol. 2016;55:381-90. doi: 10.1159/000431205. Epub 2015 Oct 26

86. Olk RJ, Peralta E, Gierhart DL, Brown MM, Brown GC. Combination therapy with dietary zeaxanthin for neovascular age-related macular degeneration. A randomized clinical trial. J Clin Exp Ophthalmol 2017; 8: 692. Doi: 10.4172/2155-9570.

87. Brown GC. Brown MM, Lieske HB, Tran I, Turpcu A, Colman S. The societal costs associated with neovascular, age-related macular degeneration in the United States. RETINA 2016; 36:285-98.

88. Brown GC, Brown MM, Lieske HB, Brown KS, Colman S, Tran I. The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited.. Int J Retina Vit (2017) 3:5 DOI 10.1186/s40942-016-0058-3

89. Yannuzzi NA, Chang JA, Brown GC, Smiddy WE. Cost-utility of evaluation for posterior vitreous detachment and prophylaxis of retinal detachment. Ophthalmology 2018; 125:43-50.

90. Brown GC, Brown MM. Age-Relate Macular Degeneration Concepts. Ophthalmology Management AMD Update, An e-newsletter, November, 2018.

91. Brown GC, Brown MM, Busbee BG, Rapuano SB. A Cost-benefit analysis of 2018 cataract surgery in the United States. Clin Res Ophthalmol 2018;1(2):1-14.

92. Brown GC, Brown MM, Lieske HB. Comparative effectiveness and cost-effectiveness analyses of the prostamides and timolol for open angle glaucoma. J Ocul Pharmacol & Therapy (in press).